Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX +4.03%24 3-Year ROIIC % is 18.65 as of Mar. 2026, which is 19% below its 10-year median of 22.95. GuruFocus rates NSE:INFLUX with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 943 Drug Manufacturers companies, Influx Healthtech ranks better than 69.67% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Influx Healthtech's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 18.65%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Influx Healthtech's 3-Year ROIIC % or its related term are showing as below:
NSE:INFLUX's 3-Year ROIIC % is ranked better than 69.67% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs NSE:INFLUX: 18.65
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Influx Healthtech 3-Year ROIIC % Related Terms
Influx Healthtech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Influx Healthtech (NSE:INFLUX) has a 3-Year ROIIC % of 18.65 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Influx Healthtech and its competitors. This is 19% below median its historical median of 22.95. Over the past decade, Influx Healthtech's 3-Year ROIIC % has ranged from 18.65 to 27.24. According to the industry distribution chart, Influx Healthtech ranks #286 out of 943 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Influx Healthtech's 3-Year ROIIC % too high?
Influx Healthtech's current 3-Year ROIIC % of 18.65 is 19% below median its 10-year median of 22.95. Over the past 10 years, this metric has ranged from a low of 18.65 to a high of 27.24. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Influx Healthtech's value of 18.65 is 423.9% above this industry median. Based on the distribution chart, Influx Healthtech ranks #286 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Influx Healthtech has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #286 out of 943 companies for 3-Year ROIIC %. This puts Influx Healthtech in the upper half of its industry. The industry median 3-Year ROIIC % is 3.56. Influx Healthtech's value of 18.65 is 423.9% above this benchmark. Historically, Influx Healthtech's own 3-Year ROIIC % has ranged from 18.65 to 27.24 over the past decade. While the company's 10-year median is 22.95 vs. the industry median of 3.56, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current 3-Year ROIIC % of 18.65 is 423.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current 3-Year ROIIC % is 18.65, which is 19% below median its own 10-year median of 22.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current 3-Year ROIIC % of 18.65. The current 3-Year ROIIC % is 18.65, which is 19% below median its 10-year median of 22.95 and 423.9% above the Drug Manufacturers industry median of 3.56. Influx Healthtech's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current 3-Year ROIIC % is 18.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
24GF Score
Get the complete analysis for NSE:INFLUX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
